Biocurious: Trivarx hones the radiation-free approach to cancer oncology
TrivarX (ASX:TRI) is developing Stable-Im, a non-radioactive imaging tool for brain cancer detection. The company acquired the technology from Nucleic, paying $250,000 and issuing performance rights. TrivarX plans to launch a phase I trial by year-end, with a budget under $1 million. CEO Dr. Danielle Meyrick emphasizes the potential of Stable-Im to complement MRI and PET imaging, offering safer and more efficient diagnostics.
How this was made
The 30-second read
Why it matters
The acquisition of Stable-Im and the planned phase I study design are the key new trading-relevant details, setting expectations for safety dosing, imaging comparison versus MRI, and future FDA pathway milestones.
Market read
Investors get a program reset, acquisition economics, and a concrete phase I plan (cohorts, indications, comparison approach, and rough cost), which can drive re-rating and trading around early-stage biotech milestones.
What to watch
The article notes milestone-linked performance rights and a relatively small cash balance, so funding needs and dilution risk could dominate near-term price action before clinical readouts.
Background
Trivarx is repositioning from mental health detection to Stable-Im, a stable-isotope, non-radioactive imaging adjunct to MRI for brain cancer.
Ticker impact
Trivarx (TRI) acquired the Stable-Im platform, “parked” mental health detection, and plans a phase I dose-escalation trial by year-end.
Likely modest positive bias if investors view Stable-Im as de-risking brain cancer imaging, but dilution/milestone overhang remains.
The article provides concrete program reset details (acquisition, parked program) and a specific trial design (15 healthy, expansion in glioblastoma/brain mets) plus cost/timing estimates, which can re-rate early-stage oncology imaging narratives.
Market effects
Highlights a shift toward non-radioactive, stable-isotope adjunct imaging in brain oncology, potentially affecting investor appetite for radiopharm-adjacent platforms.
ASX small-cap biotech focus, with US FDA submission milestones referenced via performance rights.
If Stable-Im proves safe and adds metabolic resolution to MRI, it could broaden imaging workflows beyond PET constraints.
Counterpoint
The “radiation-free” advantage may not overcome clinical differentiation versus PET/MRI, and the program could still face translational hurdles despite preclinical tolerability.
Key entities
- companyTrivarx
ASX-listed company developing Stable-Im stable-isotope imaging for brain cancer, with a planned phase I trial by year-end.
- companyNucleic
Private entity that owned the Stable-Im radiation-free imaging platform acquired by Trivarx.
- companyRacura Oncology
Referenced as led by Dr Daniel Tillett, who is also scientific adviser to Trivarx.
- organizationBeyond Drug Development
Clinical research organisation supporting the phase I study.
